Skip to content

Net Change in Cash at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.98B-86.2%
Merck & Co. logo
Merck & Co.MRK
-$9.29B-103%
CG Oncology logo
CG OncologyCGON
$1.21M+101%
Arvinas logo
ArvinasARVN
-$55.6M-185%
Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
-$6.5M-157%
Replimune Group logo
Replimune GroupREPL
$20.65M-64.8%

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$677.17M+2,907%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s net change in cash?
Relmada Therapeutics, Inc. (RLMD) reported net change in cash of $6.28M in Q1 2026.
How has Relmada Therapeutics, Inc.'s net change in cash changed year-over-year?
Relmada Therapeutics, Inc.'s net change in cash increased by 332.0% year-over-year, from -$2.71M to $6.28M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.